Related Experiment Video

Updated: Sep 21, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Studies of von Willebrand factor in essential thrombocythemia patients treated with alpha-2b recombinant interferon

M G Mazzucconi1, A Ferrari, S Solinas

  • 1Department of Human Biopathology, University La Sapienza, Rome, Italy.

Haemostasis
|January 1, 1991
PubMed

Insights

Interferon therapy in myeloproliferative disorders with thrombocytosis improves platelet counts and function. von Willebrand Factor abnormalities often normalize with treatment, suggesting therapeutic benefits.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Myeloproliferative disorders (MPD) involve abnormal blood cell production.
  • von Willebrand Factor (vWF) plays a key role in platelet function and MPD.
  • Interferon (IFN) has shown efficacy in reducing platelet counts in MPD.

Purpose of the Study:

  • To investigate the impact of alpha 2b recombinant interferon (alpha 2b-rIFN) on vWF properties in patients with essential thrombocythemia (ET) or MPD with thrombocytosis.
  • To assess changes in bleeding time (BT), ristocetin-induced platelet aggregation (RIPA), and vWF parameters before and after IFN treatment.

Main Methods:

  • Studied 20 patients with ET or MPD with thrombocytosis treated with alpha 2b-rIFN.
  • Evaluated vWF-related properties, BT, and RIPA before treatment and after achieving hematologic remission.
  • Assessed vWF antigen (vWF:Ag), vWF ristocetin cofactor (vWF:Ricof), factor VIII coagulant activity (VIII:C), and vWF multimer patterns.

Main Results:

  • Before treatment, abnormalities included prolonged BT (25%), abnormal RIPA (40%), and reduced vWF:Ag/vWF:Ricof (25%).
  • After remission, BT, VIII:C, vWF:Ag, and vWF:Ricof normalized or reached upper normal limits.
  • RIPA remained abnormal in 70% of patients post-treatment; vWF multimer loss recovered in 2 out of 3 patients.

Conclusions:

  • Alpha 2b-rIFN treatment improves platelet count and function in MPD with thrombocytosis.
  • IFN therapy appears to normalize vWF parameters and potentially restore vWF multimer structure.
  • Further research is warranted to fully elucidate the mechanisms of IFN's therapeutic effects in MPD.

More Related Videos

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

Related Concept Videos

Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...